| Literature DB >> 35027863 |
Michelle Wetzk1, Nannette Grübling1, Almuth Forberger2, Jörg Klengel1, Jan Kuhlmann1, Pauline Wimberger1, Maren Goeckenjan1.
Abstract
Objectives Endometriosis is a chronic disease which is diagnosed by surgical intervention combined with a histological work-up. Current international and national recommendations do not require the histological determination of the proliferation rate. The diagnostic and clinical importance of the mitotic rate in endometriotic lesions still remains to be elucidated. Methods In this retrospective study, the mitotic rates and clinical data of 542 patients with histologically diagnosed endometriosis were analyzed. The mean patient age was 33.5 ± 8.0 (17 - 72) years, and the mean reproductive lifespan was 21.2 ± 7.8 (4 - 41) years. Patients were divided into two groups and patients' reproductive history and clinical endometriosis characteristics were compared between groups. The study group consisted of women with confirmed mitotic figures (n = 140, 25.83%) and the control group comprised women without proliferative activity according to their mitotic rates (n = 402, 74.27%). Results Women with endometriotic lesions and histologically confirmed mitotic figures were significantly more likely to have a higher endometriosis stage (p = 0.001), deep infiltrating endometriosis (p < 0.001), ovarian endometrioma (p = 0.012), and infertility (p = 0.049). A mitotic rate > 0 was seen significantly less often in cases with incidental findings of endometriosis (p = 0.031). The presence of symptoms and basic characteristics such as age, age at onset of menarche, reproductive lifespan and parity did not differ between the group with and the group without mitotic figures. Conclusion This study shows that a simple histological assessment of the mitotic rate offers additional diagnostic value for the detection of advanced stages of endometriosis. The possible role as a predictive marker for the recurrence of endometriosis or the development of endometriosis-associated cancer will require future study. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: endometriosis; endometriosis-associated ovarian cancer; infertility; laparoscopy; mitotic rate
Year: 2022 PMID: 35027863 PMCID: PMC8747893 DOI: 10.1055/a-1580-0601
Source DB: PubMed Journal: Geburtshilfe Frauenheilkd ISSN: 0016-5751 Impact factor: 2.915
Fig. 1Flowchart showing the inclusion into the retrospective study of patients treated for endometriosis at a university center.
Table 1 Baseline characteristics of women with histologically confirmed endometriosis (n = 542). Data are presented as mean ± standard deviation (median, range) or number (%).
| Clinical characteristics | Patients |
|---|---|
|
rASRM: revised classification of the American Society of Reproductive Medicine
| |
| Age (years) | 33.5 ± 8.0 (17 – 72) |
| Obstetric history | |
No prior pregnancies (n = 537) | 313 (58.29%) |
No prior births (n = 530) | 350 (66.04%) |
| Age at onset of menarche (years) | 13.0 ± 1.50 (9 – 17) |
| Reproductive lifespan (years) | 21.2 ± 7.8 (4 – 41) |
| Mean duration of menstrual cycle (n = 286) | 29.5 ± 7.6 (13 – 90) |
| Mean duration of menstrual bleeding (n = 314) | 5.7 ± 1.8 (2 – 15) |
| Previous history of endometriosis | |
No, first diagnosis | 404 (74.54%) |
Yes, recurrent disease | 128 (23.61%) |
| Main reason for surgery | |
Acute or chronic pain | 192 (35.42%) |
Infertility | 130 (23.99%) |
Incidental finding | 100 (18.45%) |
| Symptoms prior to surgery | |
Cyclic pelvic pain | 238 (43.91%) |
Dysmenorrhea | 56 (10.33%) |
Dysuria | 42 (7.75%) |
Dyspareunia | 103 (19.00%) |
Primary and secondary infertility | 210 (38,74%) |
Abnormal uterine bleeding | 80 (14.8%) |
| Concomitant gynecological diagnoses | |
Uterine malformations | 32 (5.90%) |
| Surgery | |
Outpatient treatment | 152 (28.04%) |
Hospitalization after surgery | 390 (71.96%) |
Laparoscopy | 496 (91.51%) |
Laparotomy | 36 (6.60%) |
| Occurrence of endometriosis | |
Adenomyosis | 58 (10.70%) |
Ovarian endometriosis | 180 (33.21%) |
Deep infiltrating endometriosis | 103 (19.00%) |
Peritoneal adhesions | 185 (34.13%) |
| rASRM classification (n = 523) 1 | |
Stage I | 214 (40.92%) |
Stage II | 95 (18.16%) |
Stage III | 111 (21.22%) |
Stage IV | 103 (19.69%) |
| Hormonal treatment at the time of surgery | 102 (18.82%) |
| Mean number of probes for histological assessment | 3.2 ± 1.8 (1 – 13) |
| Mean mitotic rate | 0.4 ± 0.8 (0 – 7) |
Table 2 Clinical characteristics of the subgroups without and with mitotic figures as a marker of active proliferation in 542 women with histologically confirmed endometriosis.
| Clinical characteristics | Endometriosis without mitotic figures (n = 402) | Endometriosis with a mitotic rate ≥ 1 (n = 140) | p-value |
|---|---|---|---|
| Significant differences: * p < 0.05, ** p < 0.001. | |||
| Age (years) | 33.9 ± 8.2 (17 – 72) | 32.5 ± 7.2 (19 – 55) | 0.134 |
| Obstetric history | |||
No prior pregnancies (n = 537) | 233 (58.25%) | 80 (58.39%) | 0.772 |
No prior births (n = 530) | 263 (65.91%) | 87 (63.50%) | 0.925 |
| Age at onset of menarche (years) | 13.1 ± 1.5 (9 – 17) | 12.9 ± 1.4 (9 – 16) | 0.667 |
| Reproductive lifespan (years) | 21.9 ± 8.1 (4 – 41) | 19.4 ± 6.5 (5 – 35) | 0.023* |
| Mean duration of menstrual cycle (n = 286) | 29.3 ± 7.3 (13 – 90) | 29.9 ± 8.2 (21 – 90) | 0.643 |
| Mean duration of menstrual bleeding (n = 314) | 5.6 ± 1.8 (2 – 14) | 5.9 ± 2.0 (3 – 15) | 0.138 |
| Previous history of endometriosis (n = 397) | |||
No, first diagnosis | 305 (76.83%) | 99 (73.31%) | 0.239 |
Yes, recurrent disease | 92 (23.17%) | 36 (26.69%) | |
| Predominant reason for surgery | |||
Acute or chronic pain | 150 (37.78%) | 42 (31.11%) | 0.018* |
Infertility | 90 (22.67%) | 40 (29.62%) | 0.415 |
Diagnosis of endometriosis during surgery for other indications 1 | 83 (20.64%) | 17 (12.14%) | 0.031* |
| Symptoms prior to surgery | |||
Deep pelvic pain | 255 (63.43%) | 86 (61.42%) | 0.685 |
Dysmenorrhea | 178 (44.28%) | 60 (42.9%) | 0.843 |
Dysuria | 35 (8.71%) | 7 (5.00%) | 0.199 |
Dyspareunia | 82 (20.40%) | 21 (15.00%) | 0.171 |
Dyschezia | 44 (10.95%) | 12 (8.57%) | 0.268 |
Primary and secondary infertility | 147 (36.37%) | 63 (45.00%) | 0.049* |
Abnormal uterine bleeding | 63 (15.67%) | 17 (12.14%) | 0.336 |
| Surgery | |||
Laparoscopy | 373 (93.02%) | 123 (87.86%) | 0.036* |
Laparotomy | 23 (5.74%) | 123 (9.29%) | |
| rASRM classification (n = 523) | |||
Stage I | 179 (45.90%) | 35 (26.32%) | |
Stage II | 67 (17.18%) | 28 (21.05%) | 0.001* |
Stage III | 74 (18.97%) | 37 (27.82%) | |
Stage IV | 70 (17.95%) | 33 (24.81%) | |
| Hormonal treatment | 81 (20.15%) | 21 (15.00%) | 0.210 |
Combined oral contraceptives | 55 (13.7%) | 18 (12.9%) | 0.886 |
| Only one biopsy for histological assessment | 71 (17.67%) | 12 (8.56%) | < 0.001** |
| Occurrence of endometriosis (n = 542) | |||
Adenomyosis | 42 (10.42%) | 16 (11.43%) | 0.752 |
Ovarian endometrioma | 121 (30.31%) | 59 (42.14%) | 0.012* |
Deep infiltrating endometriosis according to the ENZIAN score | 37 (9.20%) | 32 (22.86%) | < 0.001* |
| Peritoneal adhesions | 140 (34.83%) | 45 (32.14%) | 0.606 |
| Other ovarian cysts | 49 (12.19%) | 15 (10.71%) | 0.761 |
| Uterine malformations (n = 451) | 27 (6.72%) | 5 (3.57%) | 0.214 |
Fig. 2Comparison of stages using the rASRM ( a ) and the ENZIAN score ( b ) in patients without and with detected mitotic figures as a marker of proliferative activity.